Market Overview

PiperJaffray Cuts Pacific Biosciences Q1 2016 Revs From $19.1M To $17.6M, Says 'we are now $400K below the Street', Maintains Neutral And $11 PT


Latest Ratings for PACB

Apr 2016First AnalysisInitiates Coverage onOverweight
Apr 2016MKM PartnersInitiates Coverage onNeutral
Feb 2016PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for PACB
View the Latest Analyst Ratings

Posted-In: Analyst Color Reiteration Analyst Ratings


Related Articles (PACB)

Partner Center